|
|||||
|
|
In vivo and in vitro release of ACTH by synthetic CRF |
|
| Authors: | CM Turkelson A Arimura MD Culler JB Fishback K Groot M Kanda M Luciano CR Thomas D Chang JK Chang and M Shimizu |
| Institution: | *Peninsula Laboratoires, San Carlos, CA 94070, USA aLaboratory for Molecular Neuroendocrinology Tulane University Hebert Research Center, Belle Chasse, LA 70037, USA bLaboratory for Diabetes Tulane University Hebert Research Center, Belle Chasse, LA 70037, USA cDepartment of Medicine, Tulane University School of Medicine, New Orleans, LA 70112, USA dDepartment of Anatomy, Tulane University School of Medicine, New Orleans, LA 70112, USA eVeterans Administration Medical Center, New Orleans, LA 70146, USA |
| Abstract: | The 41-residue corticotropin releasing factor (CRF) was synthesized by the solid phase method. The synthetic CRF and arginine vasopressin (AVP) were examined for ACTH releasing activity and effects on the release of 5 other pituitary hormones in vivo and in vitro. Injection of the CRF into pharmacologically blocked rats increased plasma corticosterone levels in a dose-related manner. The minimum effective dose was 1.6 x 10(-12) mol/100 g body weight. CRF also significantly stimulated release of ACTH-like immunoreactivity in a dose-related manner from rat pituitary quarters beginning at a concentration of 10(-9) M. AVP, a peptide known to have CRF activity, exhibited slightly lower corticotropin releasing activity than the CRF at equimolar dose levels. Secretion of other pituitary hormones was not appreciably altered by either the CRF or AVP. |
| Keywords: | Corticotropin releasing factor Arginine vasopressin Anterior pituitary hormones |
| 本文献已被 ScienceDirect 等数据库收录！ | |